���发背景与监管地位 — What the Evidence Shows

By Editorial Desk · published 2026-05-12 · last reviewed 2026-05-30 · Topic

heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-05-30. Numbers and descriptions here follow the published literature rather than marketing material.

研发背景与监管地位

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。

各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。

Semax Origin and Molecular Structure

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Semax at a glance

Notes from published material

The core macrocycle, prerapamycin (figure 2), is then modified (figure 3) by an additional five enzymes, which lead to the final product, rapamycin. First, the core macrocycle is modified by RapI, SAM-dependent O-methyltransferase (MTase), which O-methylates at C39. Next, a carbonyl is installed at C9 by RapJ, a cytochrome P-450 monooxygenases (P-450). Then, RapM, another MTase, O-methylates at C16. Finally, RapN, another P-450, installs a hydroxyl at C27 immediately followed by O-methylation by Rap Q, a distinct MTase, at C27 to yield rapamycin. The biosynthetic genes responsible for rapamycin synthesis have been identified. As expected, three extremely large open reading frames (ORF's) designated as rapA, rapB, and rapC encode for three extremely large and complex multienzymes, RapA, RapB, and RapC, respectively. The gene rapL has been established to code for a NAD+-dependent lysine cycloamidase, which converts L-lysine to L-pipecolic acid (figure 4) for incorporation at the end of the polyketide. The gene rapP, which is embedded between the PKS genes and translationally coupled to rapC, encodes for an additional enzyme, an NPRS responsible for incorporating L-pipecolic acid, chain termination and cyclization of prerapamycin. In addition, genes rapI, rapJ, rapM, rapN, rapO, and rapQ have been identified as coding for tailoring enzymes that modify the macrocyclic core to give rapamycin (figure 3).

=== Other work === In the initial years of his research, King focused on fundamental mechanisms of mass transfer between gases and liquids. This applied to separation processes such as absorption and distillation. Some of his other work dealt with systematic methods for synthesizing processes from component steps, such as sequencing multiple distillation columns and cascade refrigeration systems. King stopped chemical engineering research in 1999, part-way through his service as Provost and Sr. Vice President for the University of California, university-wide. When he returned in 2004 to be director of Berkeley's Center for Studies in Higher Education, he wrote a number of papers relating to university structure, function, and governance and then the book on the University of California.

==== Air purification ==== UV-C light is used in air conditioning systems as a method of improving indoor air quality by disinfecting the air and preventing microbial growth. UV-C light is effective at killing or inactivating harmful microorganisms, such as bacteria, viruses, mold, and mildew. When integrated into an air conditioning system, the ultraviolet light is typically placed in areas like the air handler or near the evaporator coil. In air conditioning systems, UV-C light works by irradiating the airflow within the system, killing or neutralizing harmful microorganisms before they are recirculated into the indoor environment. The effectiveness of it in air conditioning systems depends on factors such as the intensity of the light, the duration of exposure, airflow speed, and the cleanliness of system components. Using a catalytic chemical reaction from titanium dioxide and UVC exposure, oxidation of organic matter converts pathogens, pollens, and mold spores into harmless inert byproducts. However, the reaction of titanium dioxide and UVC is not a straight path. Several hundreds of reactions occur prior to the inert byproducts stage and can hinder the resulting reaction creating formaldehyde, aldehyde, and other VOC's en route to a final stage. Thus, the use of titanium dioxide and UVC requires very specific parameters for a successful outcome. The cleansing mechanism of UV is a photochemical process. Contaminants in the indoor environment are almost entirely organic carbon-based compounds, which break down when exposed to high-intensity UV at 240 to 280 nm.

Sources: en.wikipedia.org

Related pages on this site

• Regional notes
• Simple workbook
• Robust reference
• Balanced index
• Scheduled notes
• Automated archive
• Professional digest
• Modular briefing

Further detail

is the packing fraction of the particles. This model is not very accurate for nanoparticles for it does not take into account the interfacial layer formed by the fluid around a nanoparticle. In 2006 K. C. Leong et al proposed a new model, one which took into account the existence of an interfacial layer. They did so by considering the area around a nanoparticle and stating it exists of three separate regions. Each of them with a specific but different thermal conductivity. This resulted in the following model:

∗Fifteen puffs were chosen to estimate the nicotine delivery of one traditional cigarette. Each e-cigarette cartridge, which varies across manufacturers, and each cartridge produces 10 to 250 puffs of vapor. This correlates to 5 to 30 traditional cigarettes. A puff usually lasts for 3 to 4 seconds. A 2014 study found there is wide differences in daily puffs in experienced vapers, which typically varies from 120 to 225 puffs per day. From puff-to-puff e-cigarettes do not provide as much nicotine as traditional cigarettes. A 2016 review found "The nicotine contained in the aerosol from 13 puffs of an e-cigarette in which the nicotine concentration of the liquid is 18 mg per milliliter has been estimated to be similar to the amount in the smoke of a typical tobacco cigarette, which contains approximately 0.5 mg of nicotine."

double-strand break (DSB) The loss of continuity of the phosphate-sugar backbone in both strands of a double-stranded DNA molecule, in particular when the two breaks occur at sites that are directly across from or very close to each other on the complementary strands. Contrast single-strand break.

Sources: en.wikipedia.org

Background from the literature

Design qualification (DQ)- Demonstrates that the proposed design (or the existing design for an off-the-shelf item) will satisfy all the requirements that are defined and detailed in the User Requirements Specification (URS). Satisfactory execution of the DQ is a mandatory requirement before construction (or procurement) of the new design can be authorised. Installation qualification (IQ) – Demonstrates that the process or equipment meets all specifications, is installed correctly, and all required components and documentation needed for continued operation are installed and in place. Operational qualification (OQ) – Demonstrates that all facets of the process or equipment are operating correctly. Performance qualification (PQ) – Demonstrates that the process or equipment performs as intended in a consistent manner over time. Component qualification (CQ) – is a relatively new term developed in 2005. This term refers to the manufacturing of auxiliary components to ensure that they are manufactured to the correct design criteria. This could include packaging components such as folding cartons, shipping cases, labels or even phase change material. All of these components must have some type of random inspection to ensure that the third party manufacturer's process is consistently producing components that are used in the world of GMP at drug or biologic manufacturer. There are instances when it is more expedient and efficient to transfer some tests or inspections from the IQ to the OQ, or from the OQ to the PQ.

A derived parameter, the span — defined as (D90 − D10) / D50 — quantifies the width of the distribution; micronized active pharmaceutical ingredients used in dry powder inhaler formulations typically target a D50 of 1–5 μm and a span of approximately 1–2. Laser diffraction is often paired with complementary techniques chosen for the property under control: dynamic image analysis and scanning electron microscopy for particle shape and surface morphology; Brunauer–Emmett–Teller gas-adsorption measurement for specific surface area, which scales inversely with effective particle diameter and is more sensitive to the finest fraction than volume-weighted methods; and dynamic light scattering or sedimentation field-flow fractionation for sub-micron and nanoparticle fractions outside the lower limit of laser diffraction.

fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) or glucose tolerance test with two hours after the oral dose a plasma glucose ≥ 11.1 mmol/L (200 mg/dL) A random blood sugar of greater than 11.1 mmol/L (200 mg/dL) in association with typical symptoms or a glycated hemoglobin (HbA1c) of ≥ 48 mmol/mol (≥ 6.5 DCCT %) is another method of diagnosing diabetes. In 2009, an International Expert Committee that included representatives of the American Diabetes Association (ADA), the International Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) recommended that a HbA1c threshold of ≥ 48 mmol/mol (≥ 6.5 DCCT %) should be used to diagnose diabetes. This recommendation was adopted by the American Diabetes Association in 2010. Positive tests should be repeated unless the person presents with typical symptoms and blood sugar >11.1 mmol/L (>200 mg/dL).

Sources: en.wikipedia.org

Frequently asked questions